Half-life

0.5 h

Tmax

0.25 h

Category

peptide

Also known as: tetra-substituted-grf

Mod GRF 1-29 is a tetra-substituted analogue of sermorelin (GHRH 1-29) engineered to resist DPP-IV cleavage, giving it slightly improved stability relative to native sermorelin but still a short plasma half-life of around 30 minutes. It is functionally identical to CJC-1295 without DAC and acts as a GHRH receptor agonist. When combined with a GH secretagogue such as ipamorelin or GHRP-2, it produces a synergistic GH pulse. Most protocols dose it subcutaneously once or twice daily. Tracking injection timing, meal proximity, and response is recommended due to variability in individual GH response.

Mechanism

A modified fragment of GHRH (often called modified GRF 1-29 or CJC-1295 without DAC), engineered for improved stability relative to native GHRH(1-29). It stimulates the GHRH receptor to promote pulsatile growth-hormone release, with a short duration of action.

Research summary

Studied as a short-acting GHRH analog in early pharmacology work. It is not an FDA-approved therapeutic, and long-term human outcome data are limited.

Reported side effects

Reported effects include injection-site reactions, flushing, and headache. Effects on growth hormone and IGF-1 warrant monitoring in a clinical context. The full profile is not established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Modified GRF(1-29) / GHRH analog pharmacology · peer-reviewed endocrinology journals (2006)search PubMed for GRF 1-29 growth hormone
GHRH analog reviews · peer-reviewed review articles (2015)class context

References

Modified GRF analog stabilityDOI: 10.1210/jc.2005-1536

TrackPep là ứng dụng theo dõi. Ứng dụng chỉ ghi lại những gì bạn nhập, không bao giờ đề xuất hay tính toán lượng dùng.